Volume 29, issue 4, April 2022

131 articles in this issue

1. John M. Daly, MD: The Wise and Gentleman Surgeon

2. Does Extended Lymphadenectomy Help in Pancreatic Cancer?

3. Results and Significance of Preoperative COVID-19 Testing for Cancer Surgery in Brazil

4. Disparities in Cancer Care: Educational Initiatives

5. So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes

6. Is it Time Yet for Adjuvant Immunotherapy for Patients with DNA Mismatch Repair Deficient Gastric Cancer?

7. Low-Risk Non-mucinous Adenocarcinoma of the Appendix: When Is an Appendectomy Enough?

8. The Next Step in Tumor Board Evolution: Optimizing Care Coordination and Integration

9. Inflammation in Hepatocellular Carcinoma Patients Undergoing Hepatectomy: An Important Target for Ongoing Study

10. Lymph Node Regions of Consequence in Distal Pancreatectomy: Can We Be Selective By Tumor Location?

11. Muscle Mass Matters in Patients with Renal Cell Carcinoma, but That Is Only the Beginning…

12. Oncological Surgery During the COVID-19 Pandemic: Effectiveness of Preoperative Screening and Factors Associated with Postoperative SARS-CoV-2 Infection

13. ASO Author Reflections: Oncological Surgery during the COVID-19 Pandemic: Effectiveness of Preoperative Screening and Factors Associated with Postoperative SARS-CoV-2 Infection

14. ASO Visual Abstract: Oncological Surgery during the COVID-19 pandemic—Effectiveness of Preoperative Screening and Factors Associated with Postoperative SARS-CoV-2 Infection

15. Bias Issues in Colorectal Cancer Management: A Review

16. ASO Author Reflections: Colorectal Cancer, Bias, and the Surgeon: What is Next?

17. Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care

18. Association of Medicaid Expansion with Post-mastectomy Reconstruction Rates

19. ASO Author Reflections: Despite Medicaid Expansion, Large Disparities in Breast Reconstruction Persist

20. ASO Visual Abstract: Association of Medicaid Expansion on Postmastectomy Reconstruction Rates

21. Upstaging of Fibroepithelial Lesions: A Single-Institution Experience

22. ASO Author Reflection: The Dilemma of Fibroepithelial Lesions

23. ASO Visual Abstract: Upstaging of Fibroepithelial Lesions—A Single-Institution Experience

24. Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial

25. ASO Visual Abstract: Do Preoperative Prophylactic Antibiotics Reduce Surgical-Site Infection After Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial

26. Omitting SLNB in Breast Cancer: Is a Nomogram the Answer?

27. ASO Visual Abstract: Omitting SLNB in Breast Cancer: Is a Nomogram the Answer?

28. Prognosis Comparison Between Nipple-Sparing Mastectomy and Total Mastectomy in Breast Cancer: A Case-Control Study After Propensity Score Matching

29. Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management

30. ASO Author Reflections: How COVID-19 Impacted Breast Cancer Presentation and Management

31. ASO Visual Abstract: Impact of the COVID-19 Pandemic on Breast Cancer Stage at Diagnosis, Presentation, and Patient Management

32. The Breast Cancer Patient Experience of Telemedicine During COVID-19

33. ASO Visual Abstract: The Breast Cancer Patient Experience of Telemedicine During COVID-19

34. Young Women with Breast Cancer: Chemotherapy or Surgery First? An Evaluation of Time to Treatment for Invasive Breast Cancer

35. ASO Author Reflections: Improving Efficiency of Care for Young Women with Breast Cancer

36. ASO Visual Abstract: Young Women with Breast Cancer: Chemotherapy or Surgery First? An Evaluation of Time to Treatment for Invasive Breast Cancer

37. Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?

38. ASO Visual Abstract: Can We Successfully Deescalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma In Situ or Early-Stage Breast Cancer Undergoing Mastectomy?

39. National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies

40. ASO Author Reflections: Retroperitoneal Soft Tissue Sarcoma: A Call for Collaboration and Scientific Inquiry

41. ASO Visual Abstract: National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma—A Modern Appraisal of Variability in Therapeutic Strategies

42. Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins Are Achieved

43. ASO Author Reflections: Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins are Achieved

44. ASO Visual Abstract: Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins are Achieved

45. Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma

46. ASO Visual Abstract: The Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma (RPS)

47. Radiation Therapy in Primary Soft Tissue Sarcoma of the Superficial Trunk

48. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis

49. ASO Author Reflections: Adjuvant Chemotherapy Should not be Omitted for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability

50. Pathologic Factors Associated with Low Risk of Lymph Node Metastasis in Nonmucinous Adenocarcinoma of the Appendix

51. ASO Author Reflections: Risk Factors for Lymph Node Metastasis in Non-mucinous Adenocarcinoma of the Appendix

52. ASO Visual Abstract: Pathologic Factors Associated With Low Risk of Lymph Node Metastasis in Non-Mucinous Adenocarcinoma of the Appendix

53. Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study

54. A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy: Initial Experience Compared with Roux-en-Y Anastomosis

55. ASO Author Reflections: Totally Laparoscopic Distal Gastrectomy with Modified Billroth-II with Braun Reconstruction Could Be Technically Feasible and Effective in Preventing Bile Reflux

56. ASO Visual Abstract: A Modified Billroth-II with Braun Anastomosis in Totally Laparoscopic Distal Gastrectomy—Initial Experience Compared with Roux-en-Y Anastomosis

57. Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies

58. ASO Visual Abstract: Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies

59. Limited Prognostic Value of KRAS in Patients Undergoing Hepatectomy for Colorectal Liver Metastases

60. ASO Visual Abstract: Limited Prognostic Value of KRAS for Patients Undergoing Hepatectomy for Colorectal Liver Metastases

61. Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma

62. ASO Visual Abstract: Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma

63. Robotic Left Hepatectomy Extended to Caudate Lobe and Common Biliary Duct for Hilar Cholangiocarcinoma

64. ASO Author Reflections: Mini-Invasive Hilar Cholangiocarcinoma Resection: Could Robots Be the Key?

65. Totally Laparoscopic Tourniquet ALPPS: Technical Standardization by Combining the Pure Hanging Maneuver and the Approach Through the Sugioka Gates

66. ASO Author Reflections: Technical Steps for the Standardization of Laparoscopic Liver Tourniquet as a Modified ALPPS Procedure: A Feasible Option with Equivalent Results and Reduced Aggressiveness

67. Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location

68. ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-Peripancreatic Lymph Nodes for all Left-Sided Pancreatic Cancer Patients?

69. ASO Visual Abstract: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-sided Pancreatic Cancer Based on Tumor Location

70. Surgical Outcomes and Comparative Analysis of Transduodenal Ampullectomy and Pancreaticoduodenectomy: A Single-Center Study

71. ASO Author Reflections: Assessment of Transduodenal Ampullectomy as a Feasible Option Compared with Pancreaticoduodenectomy

72. ASO Visual Abstract: Surgical Outcomes and Analysis Comparing Transduodenal Ampullectomy with Pancreaticoduodenectomy: Single-Center Study

73. The Effect of Hospital Versus Surgeon Volume on Short-Term Patient Outcomes After Pancreaticoduodenectomy: a SEER–Medicare Analysis

74. ASO Author Reflection: Experience or Expertise: How Hospital and Surgeon Volume Affect Outcomes of Pancreaticoduodenectomy

75. ASO Visual Abstract: The Effect of Hospital Versus Surgeon Volume on Short-Term Patient Outcomes after Pancreaticoduodenectomy: A SEER-Medicare Analysis

76. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

77. Robotic Extended Ultrasound-Guided Distal Pancreatectomy for Pancreatic Metastases from Uveal Melanoma

78. ASO Author Reflections: The Role of the Robot in Minimally Invasive Pancreatectomy

79. Association Between Sarcopenia and Survival of Patients with Organ-Confined Renal Cell Carcinoma after Radical Nephrectomy

80. ASO Author Reflections: Muscle Mass Matters Even Among the Surgically Fit Patients with Early Renal Cancer

81. ASO Visual Abstract: Association Between Sarcopenia and the Survival of Patients with Organ-Confined Renal Cell Carcinoma After Radical Nephrectomy

82. Long-Term Oncological and Functional Outcomes After Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Cell Carcinoma

83. Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

84. ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

85. Long-Term Outcomes After Colorectal Surgery in Patients with Ulcerative Colitis-Associated Colorectal Cancer Versus Sporadic Colorectal Cancer

86. ASO Author Reflections: Does a Diagnosis of Ulcerative Colitis Affect Outcome in Colorectal Cancer?

87. Tailored Management with Highly-Selective Diversion for Low Colorectal Anastomosis: Biochemical Postoperative Follow-Up and Long-Term Results from a Single-Institution Cohort

88. ASO Visual Abstract: Tailored Management with Highly Selective Diversion for Low Colorectal Anastomosis—Biochemical Postoperative Follow-Up and Long-Term Results from a Single-Institution Cohort

89. The Impact of Commission on Cancer Accreditation Status, Hospital Rurality and Hospital Size on Quality Measure Performance Rates

90. ASO Visual Abstract: The Impact of Commission on Cancer Accreditation Status, Hospital Rurality, and Hospital Size on Quality Measure Performance Rates

91. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas

92. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas

93. Patterns of Occult Metastasis to Level Va and Vb in Clinically Lateral Node-Positive Papillary Thyroid Carcinoma

94. ASO Author Reflections: Patterns and Predictors of Occult Level V Lymph Node Metastasis in Papillary Thyroid Carcinoma

95. ASO Visual Abstract: Patterns of Occult Metastasis to Level Va and Vb in Clinically Lateral Node-Positive Papillary Thyroid Carcinoma

96. Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer: A Single Center Cohort Study

97. ASO Visual Abstract: Prognostic Performance of Alternative Lymph Node Classification Systems for Patients with Medullary Thyroid Cancer—A Single-Center Cohort Study

98. Survival After Adrenalectomy for Metastatic Lung Cancer

99. ASO Visual Abstract: Survival After Adrenalectomy for Metastatic Lung Cancer

100. Evaluation of Survival and Postoperative Radiation Among Patients with Advanced Medullary Thyroid Carcinoma: An Analysis of the National Cancer Database

101. ASO Visual Abstract: Evaluation of Survival and Postoperative Radiation among Patients with Advanced Medullary Thyroid Carcinoma: An Analysis of the National Cancer Database

102. Predictive Score of Nodal Involvement in Endometrial Cancer Patients: A Large Multicentre Series

103. ASO Author Reflections: How Long will We Perform Lymphadenectomy in Endometrial Cancer Patients?

104. Predictive Score of Nodal Involvement in Endometrial Cancer Patients: A Large, Multicenter Series

105. Minimally Invasive Secondary Cytoreductive Surgery for Superficial Celiac and Cardio-Phrenic Isolated Nodal Recurrence of Ovarian Cancer

106. ASO Author Reflections: Minimally Invasive Secondary Cytoreductive Surgery for Ovarian Cancer Lymph Node Recurrence: Shaping Treatment with All Arrows in our Quiver

107. Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology

108. ASO Author Reflections: Discordant Pathology in Pseudomyxoma Peritonei and Its Impact on Survival following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

109. ASO Visual Abstract: Overall Survival is More Closely Associated with Peritoneal than Primary Appendiceal Pathological Grade in Pseudomyxoma Peritonei with Discordant Pathology

110. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial

111. ASO Author Reflections: HIPEC with Cisplatin Improves Prognosis in Advanced Ovarian Cancer after Neoadjuvant Chemotherapy

112. ASO Visual Abstract: Cytoreductive Surgery with or Without HIPEC after Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase III Clinical Trial

113. Failure to Thrive Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Causes and Consequences

114. ASO Visual Abstract: Failure to Thrive Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Causes and Consequences

115. Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

116. ASO Author Reflections: Neoadjuvant Chemotherapy for High-Grade Appendiceal Neoplasms Before Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Closer to Evidence-Based Practice?

117. ASO Visual Abstract: Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

118. Functional Cerebral MRI Evaluation of Integration of Breast Reconstruction into the Body Schema

119. ASO Visual Abstract: Functional Cerebral MRI Evaluation of the Integration of Breast Reconstruction into the Body Schema

120. Albumin-Derived NLR Score is a Novel Prognostic Marker for Esophageal Squamous Cell Carcinoma

121. ASO Visual Abstract: Albumin-Derived NLR Score is a Novel Prognostic Marker for Esophageal Squamous Cell Carcinoma

122. Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor after Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

123. ASO Author Refections: Evaluation of Endoscopic Response After Neoadjuvant Chemotherapy Guides Distribution of Residual Diseases for Esophageal Squamous Cell Carcinoma

124. ASO Visual Abstract: Clinical Significance of Endoscopic Response Evaluation to Predict the Distribution of Residual Tumor After Neoadjuvant Chemotherapy for Esophageal Squamous cell Carcinoma

125. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases

126. ASO Visual Abstract: Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-abdominal Metastases

127. SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma

128. ASO Visual Abstract: SLC7A9 as a Potential Biomarker for Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma

129. Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication

130. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome

131. ASO Visual Abstract: Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Shows KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome